Literature DB >> 24857241

Effect of primary empty sella syndrome on pituitary surgery for Cushing's disease.

Gautam U Mehta1, Kamran D Bakhtian, Edward H Oldfield.   

Abstract

OBJECT: Primary empty sella syndrome (ESS) results from herniation of arachnoid mater into the pituitary fossa. It has been suggested to have a negative effect on pituitary surgery; however, outcomes in this cohort have not been defined. This study was performed to determine the effect of ESS on immediate and long-term biochemical outcome after pituitary surgery for Cushing's disease (CD).
METHODS: Using a matched cohort study design, the authors followed patients treated with pituitary surgery for CD with and without ESS. Complete ESS was defined as pituitary gland height ≤ 2 mm, whereas partial ESS was defined as pituitary gland height > 2 mm but less than three-quarters of the total sellar depth. The primary end points were immediate and long-term biochemical outcome. Cerebrospinal fluid leaks were recorded as a secondary end point.
RESULTS: Seventy-eight patients with CD and primary ESS were identified and matched with 78 patients with CD without ESS. After surgical management, immediate biochemical remission was achieved in 69 patients (88%) with ESS and 75 controls (96%, p = 0.10). Long-term remission was achieved in most patients in both groups (5-year cure: 85% vs 92%, p = 0.10). Among patients with ESS, the presence of complete ESS predicted a worse long-term outcome (p = 0.04). Intraoperative CSF leaks were significantly more frequent with ESS (54% vs 24%, p < 0.001), and despite sellar floor repair, the rate of postoperative CSF leaks was also increased (6% vs 3%, p = 0.27).
CONCLUSIONS: Biochemical outcome after pituitary surgery for CD was worse in patients with complete ESS, and the risk of a CSF leak was increased with both partial and complete ESS. However, as outcome remains superior to those following alternative therapies and the biology of these tumors is unchanged in the setting of ESS, pituitary surgery should remain the initial treatment of choice.

Entities:  

Keywords:  ACTH = adrenocorticotropin; BMI = body mass index; CD = Cushing's disease; CRH = corticotropin-releasing hormone; Cushing's disease; DI = diabetes insipidus; ESS = empty sella syndrome; GH = growth hormone; SIADH = syndrome of inappropriate antidiuretic hormone; UFC = urinary free cortisol; empty sella syndrome; pituitary adenoma; pituitary surgery; transsphenoidal surgery

Mesh:

Substances:

Year:  2014        PMID: 24857241     DOI: 10.3171/2014.3.JNS132012

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  5 in total

1.  Effects of preoperative bromocriptine treatment on prolactin-secreting pituitary adenoma surgery.

Authors:  Yingxiao Cao; Fengju Wang; Zhenbo Liu; Baohua Jiao
Journal:  Exp Ther Med       Date:  2016-03-02       Impact factor: 2.447

2.  Delayed Diagnosis of Cushing's Disease in a Pediatric Patient due to Apparent Remission from Spontaneous Apoplexy.

Authors:  Sara H Rahman; Prashant Chittibonia; Martha Quezado; Nicholas Patronas; Constantine A Stratakis; Maya B Lodish
Journal:  J Clin Transl Endocrinol Case Rep       Date:  2016-12

3.  Clinical characteristics of acromegalic patients with empty sella and their outcomes following transsphenoidal surgery.

Authors:  Yasuo Sasagawa; Yasuhiko Hayashi; Osamu Tachibana; Masahiro Oishi; Issei Fukui; Hideaki Iizuka; Mitsutoshi Nakada
Journal:  Pituitary       Date:  2017-08       Impact factor: 4.107

4.  Efficacy of sellar opening in the pituitary adenoma resection of transsphenoidal surgery influences the degree of tumor resection.

Authors:  Shousen Wang; Yong Qin; Deyong Xiao; Liangfeng Wei
Journal:  BMC Med Imaging       Date:  2017-07-24       Impact factor: 1.930

5.  THYMIC CARCINOID WITH ADRENOCORTICOTROPIC HORMONE-PRODUCING ECTOPIC CUSHING SYNDROME AND EMPTY SELLA.

Authors:  Artak Labadzhyan; Se-Min Kim; Jane Rhyu; Takako Araki; Ali Mahtabifard; Shlomo Melmed
Journal:  AACE Clin Case Rep       Date:  2018-05-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.